Institution
University of Copenhagen
Education•Copenhagen, Denmark•
About: University of Copenhagen is a education organization based out in Copenhagen, Denmark. It is known for research contribution in the topics: Population & Medicine. The organization has 57645 authors who have published 149740 publications receiving 5903093 citations. The organization is also known as: Copenhagen University & Københavns Universitet.
Topics: Population, Medicine, Galaxy, Diabetes mellitus, Cancer
Papers published on a yearly basis
Papers
More filters
••
Flanders Marine Institute1, University of New South Wales2, Australian Museum3, University of Southern Mississippi4, National Oceanography Centre, Southampton5, University of Hasselt6, WorldFish7, American Museum of Natural History8, San Diego State University9, Museum Victoria10, Natural History Museum11, Dowling College12, University of Hamburg13, University of Johannesburg14, James Cook University15, National Museum of Natural History16, National Taiwan Ocean University17, Scripps Institution of Oceanography18, National Oceanic and Atmospheric Administration19, University of Queensland20, University of Sassari21, Vrije Universiteit Brussel22, Université libre de Bruxelles23, Queensland Museum24, University of California, Merced25, Ghent University26, Naturalis27, Howard University28, University of Gothenburg29, California Academy of Sciences30, Florida Museum of Natural History31, Centre for Environment, Fisheries and Aquaculture Science32, Osaka University33, University of Santiago de Compostela34, University of Alaska Anchorage35, University of Málaga36, National Institute of Water and Atmospheric Research37, National University of Ireland, Galway38, University of Alaska Fairbanks39, Spanish National Research Council40, CABI41, University of Siegen42, Massey University43, University of Copenhagen44, Naturhistorisches Museum45, University of Washington46, Museum für Naturkunde47, Woods Hole Oceanographic Institution48, Western Washington University49, University of Bergen50, Nova Southeastern University51, Shirshov Institute of Oceanology52, National University of Singapore53, Shimane University54, Agnes Scott College55, University of the Ryukyus56, University of California, Davis57, Federal University of Paraná58, University of the Basque Country59, University of Veterinary Medicine Hanover60, Royal Belgian Institute of Natural Sciences61, Tel Aviv University62, Swedish Museum of Natural History63, Joint Nature Conservation Committee64, The Evergreen State College65, Estonian University of Life Sciences66, University of Maine67, Virginia Commonwealth University68, Trinity College, Dublin69, University of Auckland70
TL;DR: The first register of the marine species of the world is compiled and it is estimated that between one-third and two-thirds of marine species may be undescribed, and previous estimates of there being well over one million marine species appear highly unlikely.
822 citations
••
University of Groningen1, Showa University2, University of Chicago3, AbbVie4, University of Glasgow5, University of Copenhagen6, Mario Negri Institute for Pharmacological Research7, University of Texas Southwestern Medical Center8, University of California, Irvine9, University of Würzburg10, Stanford University11
TL;DR: Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of end-stage renal disease (ESRD) or death from cardiovascular causes and was terminated on the recommendation of the independent data and safety monitoring committee.
Abstract: BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to <30 ml per minute per 1.73 m(2) of body-surface area) to bardoxolone methyl, at a daily dose of 20 mg, or placebo. The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascular causes. RESULTS: The sponsor and the steering committee terminated the trial on the recommendation of the independent data and safety monitoring committee; the median follow-up was 9 months. A total of 69 of 1088 patients (6%) randomly assigned to bardoxolone methyl and 69 of 1097 (6%) randomly assigned to placebo had a primary composite outcome (hazard ratio in the bardoxolone methyl group vs. the placebo group, 0.98; 95% confidence interval [CI], 0.70 to 1.37; P=0.92). In the bardoxolone methyl group, ESRD developed in 43 patients, and 27 patients died from cardiovascular causes; in the placebo group, ESRD developed in 51 patients, and 19 patients died from cardiovascular causes. A total of 96 patients in the bardoxolone methyl group were hospitalized for heart failure or died from heart failure, as compared with 55 in the placebo group (hazard ratio, 1.83; 95% CI, 1.32 to 2.55; P<0.001). Estimated GFR, blood pressure, and the urinary albumin-to-creatinine ratio increased significantly and body weight decreased significantly in the bardoxolone methyl group, as compared with the placebo group. CONCLUSIONS: Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes. A higher rate of cardiovascular events with bardoxolone methyl than with placebo prompted termination of the trial. (Funded by Reata Pharmaceuticals; BEACON ClinicalTrials.gov number, NCT01351675.).
821 citations
••
TL;DR: It is suggested that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
Abstract: The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side-viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7-36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1-(9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
820 citations
••
The Royal Marsden NHS Foundation Trust1, Erasmus University Rotterdam2, Leiden University Medical Center3, University of Kiel4, University of Tübingen5, Katholieke Universiteit Leuven6, Netherlands Cancer Institute7, University College Hospital8, University of Mannheim9, University of Copenhagen10, McGill University11, Montreal General Hospital12, European Organisation for Research and Treatment of Cancer13, Radboud University Nijmegen14
TL;DR: This phase 3 randomised controlled trial assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorbicin alone.
Abstract: Summary Background Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide—which have been used to treat soft-tissue sarcoma for more than 30 years—still have an important role Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial We assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorubicin alone Methods We did this phase 3 randomised controlled trial (EORTC 62012) at 38 hospitals in ten countries We included patients with locally advanced, unresectable, or metastatic high-grade soft-tissue sarcoma, age 18–60 years with a WHO performance status of 0 or 1 They were randomly assigned (1:1) by the minimisation method to either doxorubicin (75 mg/m 2 by intravenous bolus on day 1 or 72 h continuous intravenous infusion) or intensified doxorubicin (75 mg/m 2 ; 25 mg/m 2 per day, days 1–3) plus ifosfamide (10 g/m 2 over 4 days with mesna and pegfilgrastim) as first-line treatment Randomisation was stratified by centre, performance status (0 vs 1), age ( vs ≥50 years), presence of liver metastases, and histopathological grade (2 vs 3) Patients were treated every 3 weeks till progression or unacceptable toxic effects for up to six cycles The primary endpoint was overall survival in the intention-to-treat population The trial is registered with ClinicalTrialsgov, number NCT00061984 Findings Between April 30, 2003, and May 25, 2010, 228 patients were randomly assigned to receive doxorubicin and 227 to receive doxorubicin and ifosfamide Median follow-up was 56 months (IQR 31–77) in the doxorubicin only group and 59 months (36–72) in the combination group There was no significant difference in overall survival between groups (median overall survival 12·8 months [95·5% CI 10·5–14·3] in the doxorubicin group vs 14·3 months [12·5–16·5] in the doxorubicin and ifosfamide group; hazard ratio [HR] 0·83 [95·5% CI 0·67–1·03]; stratified log-rank test p=0·076) Median progression-free survival was significantly higher for the doxorubicin and ifosfamide group (7·4 months [95% CI 6·6–8·3]) than for the doxorubicin group (4·6 months [2·9–5·6]; HR 0·74 [95% CI 0·60–0·90], stratified log-rank test p=0·003) More patients in the doxorubicin and ifosfamide group than in the doxorubicin group had an overall response (60 [26%] of 227 patients vs 31 [14%] of 228; p vs 40 [18%] of 223 patients), neutropenia (93 [42%] vs 83 [37%]), febrile neutropenia (103 (46%) vs 30 [13%]), anaemia (78 [35%] vs 10 [5%]), and thrombocytopenia (75 [33%]) vs one [ Interpretation Our results do not support the use of intensified doxorubicin and ifosfamide for palliation of advanced soft-tissue sarcoma unless the specific goal is tumour shrinkage These findings should help individualise the care of patients with this disease Funding Cancer Research UK, EORTC Charitable Trust, UK NHS, Canadian Cancer Society Research Institute, Amgen
819 citations
••
University of Cambridge1, University of Kiel2, University of East Anglia3, University of Copenhagen4, University of Manchester5, Karolinska Institutet6, Maastricht University7, Wellcome Trust Sanger Institute8, Trinity College, Dublin9, University of Paris10, University of Birmingham11, Charles University in Prague12, University College London13, University of Parma14, University of Jena15, Lund University16, University of Glasgow17, Imperial College London18, GlaxoSmithKline19, Linköping University20, Ruhr University Bochum21, University of Erlangen-Nuremberg22, Medical University of Vienna23
TL;DR: This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyang iitis and microscopic polyangiitis that are associated with ANCA specificity, and suggests that the response against the autoantigen proteinase 3 is a central pathogenic feature ofproteinase 3 ANCA -associated vasulitis.
Abstract: BACKGROUND Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a severe condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) and microscopic polyangiitis. Its cause is unknown, and there is debate about whether it is a single disease entity and what role ANCA plays in its pathogenesis. We investigated its genetic basis. METHODS A genomewide association study was performed in a discovery cohort of 1233 U. K. patients with ANCA-associated vasculitis and 5884 controls and was replicated in 1454 Northern European case patients and 1666 controls. Quality control, population stratification, and statistical analyses were performed according to standard criteria. RESULTS We found both major-histocompatibility-complex (MHC) and non-MHC associations with ANCA-associated vasculitis and also that granulomatosis with polyangiitis and microscopic polyangiitis were genetically distinct. The strongest genetic associations were with the antigenic specificity of ANCA, not with the clinical syndrome. Anti-proteinase 3 ANCA was associated with HLA-DP and the genes encoding alpha(1)-antitrypsin (SERPINA1) and proteinase 3 (PRTN3) (P = 6.2x10(-89), P = 5.6x10(-12), and P = 2.6x10(-7), respectively). Anti-myeloperoxidase ANCA was associated with HLA-DQ (P = 2.1x10(-8)). CONCLUSIONS This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyangiitis and microscopic polyangiitis that are associated with ANCA specificity, and suggests that the response against the autoantigen proteinase 3 is a central pathogenic feature of proteinase 3 ANCA-associated vasculitis. These data provide preliminary support for the concept that proteinase 3 ANCA-associated vasculitis and myeloperoxidase ANCA-associated vasculitis are distinct autoimmune syndromes. (Funded by the British Heart Foundation and others.)
816 citations
Authors
Showing all 58387 results
Name | H-index | Papers | Citations |
---|---|---|---|
Michael Karin | 236 | 704 | 226485 |
Matthias Mann | 221 | 887 | 230213 |
Peer Bork | 206 | 697 | 245427 |
Ronald Klein | 194 | 1305 | 149140 |
Kenneth S. Kendler | 177 | 1327 | 142251 |
Dorret I. Boomsma | 176 | 1507 | 136353 |
Ramachandran S. Vasan | 172 | 1100 | 138108 |
Unnur Thorsteinsdottir | 167 | 444 | 121009 |
Mika Kivimäki | 166 | 1515 | 141468 |
Jun Wang | 166 | 1093 | 141621 |
Anders Björklund | 165 | 769 | 84268 |
Gerald I. Shulman | 164 | 579 | 109520 |
Jaakko Kaprio | 163 | 1532 | 126320 |
Veikko Salomaa | 162 | 843 | 135046 |
Daniel J. Jacob | 162 | 656 | 76530 |